GlassScriptPhysician profile
Keith H Lamy
NPI 1164430278
$4,449.99
in general payments reported to CMS, 2019-2025
33 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $1,092 · 2021: $510 · 2022: $420 · 2023: $484 · 2024: $556 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $589.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $510.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $491.08 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $408.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.29 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $289.45 | 2022-2025 | |
| Amgen INC. | $256.73 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $187.23 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $184.57 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Genzyme Corporation | $150.00 | 2019-2020 | |
| Astellas Pharma US INC | $117.59 | 2019-2020 | |
| Optos, INC. | $115.96 | 2021 | |
| Abbvie INC. | $109.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $93.02 | 2019-2025 | Spravato |
| Abbott Laboratories | $84.56 | 2022-2025 | Freestyle Libre 3, Proclaim |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.50 | 2020 | |
| Exact Sciences Corporation | $53.47 | 2025 | Cologuard Collection Kit |
| Abiomed | $48.57 | 2024 | Impella |
| Pfizer INC. | $36.15 | 2024 | |
| Daiichi Sankyo INC. | $33.23 | 2020 | |
| Amarin Pharma, INC. | $31.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.27 | 2019 | |
| Dexcom, INC. | $25.20 | 2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $24.11 | 2021 | |
| Harmony Biosciences LLC | $22.50 | 2024 | |
| Shield Therapeutics INC | $19.62 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $18.52 | 2023 | |
| Convatec INC. | $18.40 | 2023 | |
| Corcept Therapeutics | $17.65 | 2022 | |
| Sanofi Pasteur INC. | $16.69 | 2019 | |
| Endo Pharmaceuticals INC. | $15.76 | 2020 | |
| Hikma Pharmaceuticals USA | $15.10 | 2019 | |
| Horizon Therapeutics Plc | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.